In an update to their previous 2007 statement, the AHA and ADA recently presented a review of the current literature and key clinical trials regarding blood pressure and glucose control, cholesterol management, aspirin therapy, and lifestyle modification for primary prevention of CVD in patients with type 2 diabetes. Both the AHA and ADA believed an update was in order due to the major changes that have occurred in the past several years in each of the “ABC” elements of diabetes care (HbA1c, blood pressure, and cholesterol), and because CVD remains the leading cause of death among patients with type 2 diabetes. Read more
Physicians will soon have a new financial incentive to focus on CVD prevention through the Million Hearts® CVD Risk Reduction Model. The Centers for Medicare & Medicaid Services (CMS) will reward providers for reducing the absolute 10-year risk of heart disease or stroke among their high-risk patients, utilizing a predictive model to generate personalized risk scores and treatment plans. The national initiative is aiming to prevent one million heart attacks and strokes by 2017.